6 active not recruiting, 3 completed, 3 recruiting, 3 terminated. 20 Phase 1, 11 Phase 2.
Follow Turcot syndrome: new trials by email Literature Review of Turcot syndrome trials Research Report on Turcot syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC) DES-1357 - Metastatic Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Not yet recruiting | D. E. Shaw Research, LLC | 88 | 2026-12-03 | 2026-09-08 |
| Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency Pembrolizumab, Navifus Focused Ultrasound Sonification - Glioblastoma, Mismatch Repair Deficiency | Phase 1 | Not yet recruiting | Jennifer Leddon | 8 | 2026-06-01 | 2026-02-04 |
| EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors EIK1005, pembrolizumab (KEYTRUDA® ) - Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Eikon Therapeutics | 160 | 2026-01-20 | 2026-10-30 |
| A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors GSK5460025 - Neoplasms, Colorectal, Neoplasms | Phase 1 / Phase 2 | Recruiting | GlaxoSmithKline | 47 | 2025-10-20 | 2026-09-16 |
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors GSK4418959, PD-1 inhibitor - Neoplasms, Colorectal, Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 14 | 2024-12-13 | 2026-02-02 |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Alintegimod, Ipilimumab, Nivolumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 7 Hills Pharma, LLC | 126 | 2024-08-23 | 2026-04-13 |
| Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types MT-8421, Nivolumab - Non Small Cell Lung Cancer, Hepatocellular Carcinoma | Phase 1 | Terminated | Molecular Templates, Inc. | 15 | 2023-11-01 | 2024-11-01 |
| Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors INCB 99280 with Ipilimumab - Melanoma, Hepatocellular Carcinoma (HCC) | Phase 1 | Terminated | Incyte Corporation | 8 | 2023-08-29 | 2025-02-18 |
| Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. HRO761, pembrolizumab, irinotecan - MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 123 | 2023-06-27 | 2026-10-21 |
| Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer Cadonilimab - Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR) | Phase 1 / Phase 2 | Active not recruiting | Sun Yat-sen University | 28 | 2023-02-07 | 2026-06-24 |
| T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors Pembrolizumab, E7777 - Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Active not recruiting | Alexander B Olawaiye, MD | 25 | 2022-09-30 | 2026-05-29 |
| A Beta-only IL-2 ImmunoTherapY Study MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | Medicenna Therapeutics, Inc. | 160 | 2021-08-27 | 2026-10-30 |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Biospecimen Collection, Ipilimumab, Nivolumab - Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2021-05-11 | 2026-06-10 | |
| Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer Sintilimab, Hypofractionated Radiotherapy - Anti-PD-1 Antibody, Radiotherapy | Phase 1 / Phase 2 | Unknown | West China Hospital | 20 | 2020-08-14 | 2024-08-06 |
| SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas SL-279252 - Squamous Cell Carcinoma of the Head and Neck, Melanoma | Phase 1 | Completed | Shattuck Labs, Inc. | 49 | 2019-03-26 | 2025-04-02 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies INCAGN02390 - Cervical Cancer, Gastric Cancer | Phase 1 | Completed | Incyte Corporation | 40 | 2018-09-24 | 2021-11-15 |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib - Colorectal Cancer Not MSI-H or MMR-deficient, GIST | Phase 1 / Phase 2 | Unknown | Institut Bergonié | 747 | 2018-05-04 | 2023-03-03 |
| Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers Nivolumab - Refractory or Recurrent Hypermutated Malignancies, Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients | Phase 1 / Phase 2 | Terminated | The Hospital for Sick Children | 11 | 2017-05-15 | 2026-11-05 |
| APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors APL-501 - Solid Tumor, Microsatellite Instability | Phase 1 | Completed | Apollomics (Australia) Pty. Ltd. | 30 | 2017-03-27 | 2022-05-09 |
| Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging - Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 71 | 2015-06-03 | 2026-07-20 |
Colorectal Neoplasms (8) · Carcinoma, Renal Cell (7) · Melanoma (6) · Carcinoma, Hepatocellular (5) · Carcinoma, Non-Small-Cell Lung (5) · Neoplasm Metastasis (5) · Carcinoma, Transitional Cell (4) · Endometrial Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Mesothelioma, Malignant (3) · Rectal Neoplasms (3) · Stomach Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Uterine Cervical Neoplasms (3)
Neoplasms (17) · Neoplasms by Site (17) · Digestive System Diseases (15) · Digestive System Neoplasms (15) · Gastrointestinal Diseases (15) · Gastrointestinal Neoplasms (15) · Intestinal Diseases (12) · Intestinal Neoplasms (12) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Neoplasms by Histologic Type (11) · Neoplasms, Glandular and Epithelial (11) · Urogenital Diseases (11) · Urogenital Neoplasms (11) · Colonic Diseases (10)
pembrolizumab (6) · Nivolumab (4) · Ipilimumab (3) · Specimen Handling (2) · CTLA-4 Antigen (1) · Clinical Trials, Phase II as Topic (1) · Diffusion Tensor Imaging (1) · E7777 fusion protein (1) · Immune Checkpoint Inhibitors (1) · Interleukin-2 (1) · Irinotecan (1) · Magnetic Resonance Spectroscopy (1) · Radiation Dose Hypofractionation (1) · denileukin diftitox (1) · regorafenib (1)
GlaxoSmithKline (2) · Incyte Corporation (2) · National Cancer Institute (NCI) (2) · 7 Hills Pharma, LLC (1) · Alexander B Olawaiye, MD (1) · Apollomics (Australia) Pty. Ltd. (1) · D. E. Shaw Research, LLC (1) · Eikon Therapeutics (1) · Institut Bergonié (1) · Jennifer Leddon (1) · Medicenna Therapeutics, Inc. (1) · Molecular Templates, Inc. (1) · Novartis Pharmaceuticals (1) · Shattuck Labs, Inc. (1) · Sun Yat-sen University (1)
United States (15) · Canada (7) · Spain (6) · Australia (5) · France (5) · Belgium (4) · South Korea (4) · China (3) · Italy (3) · Japan (3) · Germany (2) · Israel (2) · Netherlands (2) · Norway (2) · Portugal (2)
Admasu Mamuye, MD (1) · Alexander Olawaiye, MD (1) · Arash Yavari, MBBS (1) · Daniel A Morgenstern (1) · Daniel A Morgenstern, MB BChir PhD (1) · Eugene I Hwang (1) · Lionel Lewis, MA, MB.Bch, MD (1) · Marietta Franco (1) · Meng Qiu, M.D. (1) · Nawel Bourayou, MD (1) · Nilou Mobashery, MD (1) · Nina Merchant (1)
PMID 33535600, PMID 34965951, PMID 34998048, PMID 35235414, PMID 35352512, PMID 38022532, PMID 40042547, PMID 40204996, PMID 40579407
2023 (2), 2016 (1), 2025 (1), P30CA015704 (1), UM1CA081457 (1), UM1CA154967 (1)